Characterization of PAPP-A Patterns in Chronic Rhinosinusitis Authors: Afaf Ennahal, Olaf Wendler, Vanessa Vivien Pesold, Sarina Katrin Mueller Published: 2026 ABSTRACT AbstractPurposeHigh-level expression of pappalysin-A/insulin-like growth factor binding protein/insulin-like growth factor-1 (PAPP-A/IGFBP-4/5/IGF-1 axis) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) was previously demonstrated by our group. PAPP-A plays a key role in inflammatory diseases and cancer. The aim of this study was to localize PAPP-A in Chronic Rhinosinusitis (CRS), within tissue, inflammatory and different primary cells.Patients and MethodsPAPP-A was localized by immunohistochemistry (IHC) in tissues of CRSwNP (n=41), CRSsNP patients (n=12) as well as in controls (n=12). The data of eosinophil abundance in CRSwNP tissues was obtained from routine pathology. ELISA was used to quantify PAPP-A and ECP non-invasively in CRSwNP mucus (n=67). On a cellular level, PAPP-A was localized by immunofluorescence (IF) in immune and primary cells from CRSwNP (n=18).ResultsIHC revealed three distribution patterns of PAPP-A in CRSwNP correlated to the eosinophil abundance. Moreover, IF of different immune cells confirmed the high PAPP-A synthesis by eosinophils, in addition to unspecified subpopulation of T-cells and moderately in mast cells. Besides, a vesicular distribution of PAPP-A in the cytoplasm and the membrane of epithelial and fibroblast cells was shown. Finally, ECP and PAPP-A proved a significant correlation in CRSwNP mucus.ConclusionOur work is the first to illustrate the three distribution patterns of PAPP-A in CRSwNP. This underlines the potential inflammatory role of PAPP-A, particularly in CRSwNP. Targeting the PAPP-A/IGFBP/IGF-1-axis may be a new therapeutic approach for CRSwNP with high eosinophil abundance.Keywords: chronic rhinosinusitis, chronic rhinosinusitis with nasal polyps, inflammation, mucus, PAPP-A Introduction Chronic rhinosinusitis (CRS) is defined as an inflammation of the nasal mucosa (NM) lasting longer than three months. The clinical symptoms of pain, nasal obstruction, nasal discharge and a loss of smell and taste represent a high burden for the patients. Based on the external appearance of the NM, a distinction is made between chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic rhinosinusitis without nasal polyps (CRSsNP). Furthermore, CRS can be divided into three different endotypes, 1, 2 or 3, depending on whether Th1, Th2 or Th17 cells dominate in the tissue.1 The mainly symptom-based treatment and the operative removal of the inflamed tissues often do not represent satisfactory solutions, as shown by high relapse rates.2 Therefore, the complete elucidation of the pathological mechanisms is an important task. New CRS-associated factors are constantly being discovered in the tissue, mucus and serum of those affected.3 However, the complexity of the disease has not been fully elucidated so far. Current findings by our group describe a connection between CRS and the pappalysin-1 (PAPP-A)/ insulin-like growth factor binding protein 4/5 (IGFBP-4/5)/ insulin-like growth factor 1 (IGF-1)-axis for the first time.4,5 By interacting with IGFBP 4 and 5, PAPP-A causes the release of IGF-1, which stimulates cell proliferation, remodelling, metabolism and the pathogenesis of various diseases.6,7 The PAPP-A-pathway was previously proven to be involved in many physiological and pathophysiological conditions. Because of its high expression in female placenta, the protein is used as a prenatal biomarker for Down syndrome. It has an important physiological role during the pregnancy by affecting the placenta function through IGF activation, thus, regulation of fetal growth.6 The local bioavailability of PAPP-A in adult men and non-pregnant women is low, and is found in a wide range of tissues and cell types, eg adipose tissue, human osteoblasts, prostate, kidney, endometrium, fibroblasts, endothelial cells and mammary epithelial cells.8,9 Aside from the pregnancy, a high local expression of PAPP-A is related to a presence of an inflammation. In addition, PAPP-A plays an interesting role in wound healing after injury.10,11 Different studies revealed the pro-inflammatory role of PAPP-A pathway in many clinical cases such as atherosclerosis, cardiovascular events (especially in acute coronary syndrome (ACS)), renal transplantation, diabetic nephropathy, cancer and asthma. Thus, PAPP-A is considered as an inflammatory biomarker and as a potential therapeutic target for these diseases.11–13 Previous studies using CRSwNP patients revealed a significantly higher concentration of PAPP-A protein and RNA in tissue of nasal polyps (NP). Correspondingly, the cleavage products IGFBP-4 and-5 and IGF-1 and also the PAPP-A inhibitors stanniocalcin (STC) 1 and STC 2 were decreased. Moreover, PAPP-A was detected by immunohistochemistry (IHC) in eosinophils and mast cells.4 Additionally, PAPP-A concentration in nasal mucus was found to increase with disease severity and thus to predict the need for recurrent surgery.5 These findings, mainly observed in CRSwNP, are particularly relevant in the context of the distinct inflammatory endotypes characterizing CRS. Since CRSwNP is predominantly associated with type 2 endotype marked by eosinophilic infiltration and Th2-driven signalling, while CRSsNP exhibits a mixed inflammatory signature of type 1 or type 3 inflammatory signature,14,15 the potential PAPP-A expression through these endotypes may reflect and potentially contribute to their distinct pathological features. Nevertheless, only little is known about the expression pattern in sinus tissues and cells. Therefore, the objectives of this study were 1) to display the localization of PAPP-A in different inflammatory CRS phenotypes (CRSsNP, CRSwNP), 2) to analyse the occurrence of PAPP-A in detail within different inflammatory cells in NP and 3) to assess the pattern of PAPP-A in primary fibroblasts and epithelial cell cultures of NP. To our knowledge, this is the first study to characterize PAPP-A expression patterns with particular emphasis on its association with the eosinophilic inflammatory profile of CRSwNP, suggesting the pro-inflamamtory role of PAPP-A in the pathophysiology of this disease. Material and Methods Patients The protocol and consent forms of this study are approved by the institutional review board of the University of Erlangen-Nürnberg (No.: 17–269_1-B) on 07.05.2019. The study was conducted between March 2023 and October 2024. The clinical and demographic data was analysed pseudonymously and all patients gave informed consent. The diagnosis of CRSsNP and CRSwNP was made based on criteria described in the International consensus statement on allergy and rhinology (ICAR-RS) 2021.1 The study was carried out in the department of Otorhinolaryngology- Head and Neck Surgery and included CRS patients that underwent surgery for Functional Endoscopic Sinus Surgery (FESS), removal of NP, and septoplasty and turbinate reduction if needed. Additionally, control group included nasal tissue from non-CRS patients that underwent septorhinoplasty and/or turbinate reduction. However, exclusion criteria included patients with ciliary dysfunction, autoimmune disease, cystic fibrosis, immunodeficiency, malignancies, gastroesophageal reflux disease, chronic rheumatic disease, atherosclerosis, ACS, renal transplantation, diabetic nephropathy, cancer or any other disease requiring long-term (> 1 year) corticosteroid, antibiotics, monoclonal antibody therapy (biologics eg, dupilumab, mepolizumab, omalizumab) and montelukast. The data of local and circulatory eosinophil abundance in CRSwNP cases were obtained from routine analysis of patient samples in the pathological institute and the central laboratory of University Hospital Erlangen. Therefore, the eosinophil profile in tissue was classified into: high, low/focal or no eosinophil. Tissue Analysis by IHC The Zytochem-Plus AP Polymer-Kit (Zytomed Systems, Bargteheide, Germany) was used to localize PAPP-A in surgical-collected tissues from CRSwNP, CRSsNP and healthy patients. After deparaffinisation of the paraffin-embedded sections, an antigen retrieval was performed by incubating them either in Tris-EDTA buffer at 95°C for 20 minutes. Subsequently, the sections were covered with BLOXALL™ (Vector Laboratories, CA, USA) for 10 minutes to reduce the background staining. Then, the proteins were blocked with a blocking solution (included in the kit). The antibody rabbit Anti-PAPP-A1 (Cat.PB9306; Boster Biological Technology, CA, USA) and a non-specific antibody for the negative control (Cell Signaling Technology Europe, Leiden, The Netherlands) were incubated overnight at 4°C. Thereafter, the ZytoChem-Plus AP Reagent was applied and the antigens were stained with SIGMAFAST™ Fast Red TR/Naphthol AS-MX tablets (Sigma-Aldrich, Taufkirchen, Germany). At last, a counterstaining was realized with Harris’ hematoxylin solution (ORSAtec GmbH, Bobingen, Germany). And the sections were covered with Aquatex (Merck, Darmstadt, Germany).16 Tissue Analysis by Immunofluorescence (IF) In order to co-stain PAPP-A and cell specific markers of different inflammatory cells (mast cells, eosinophils, T-cells, B-cells and macrophages), an immunofluorescence in surgical-collected CRSwNP tissue slices was performed after paraffin-embedding. To allow the antibody binding by making the epitope available, a deparaffinization and heat-mediated antigen retrieval using Tris-EDTA buffer at 95°C for 20 minutes was carried out. Afterward, the sections were covered with 1% Bovine Serum Albumin (BSA) in TBS for 20 minutes in order to reduce the background staining, and with TrueBlack® Lipofuscin Autofluorescence Quencher (Biotium, Fremont, USA) 1:40 diluted in TBS for 6 minutes in order to reduce the autofluorescence. The following diluted primary antibodies in 0.1% BSA in TBS were incubated over night at 4 °C: mouse-Anti-tryptase (Cat.08506; DAKO-Agilent, Santa-Clara, USA); mouse Anti-CD3e (Cat.TA506064S; OriGene Technologies, Rockville, USA); mouse Anti-ECP (Cat.MA5-43604; ThermoFischer Scientific, Bonn, Germany); mouse Anti-CD163 (Cat.TA506380S; OriGene Technologies, Rockville, USA); mouse Anti-CD20 (Cat.MS-431-P0; Dianova Biozol, Hamburg, Germany); mouse Anti-HNE (Cat.bs-6313R; Biozol, Hamburg, Germany). Nonspecific antibodies (Cell Signaling Technology Europe, Leiden, the Netherlands) served as negative controls. Then, the following secondary antibodies diluted to a final concentration of 0.1 µg/mL in 0.1% BSA in TBS were incubated at room temperature (RT) for 1 hour: IgG (H+L) Goat Anti-Mouse, Alexa Fluor™ 555, Superclonal™ (polyclonal; ThermoFischer Scientific, Bonn, Germany) and IgG (H+L) Goat Anti-Rabbit, Alexa Fluor™ 488, Superclonal™ (polyclonal; ThermoFischer Scientific, Bonn, Germany). 4′, 6-Diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma-Aldrich, Taufkirchen, Germany) was used to stain the nuclei. The sections were covered with Mowiol for mounting.17 Primary Cell Analysis by Immunofluorescence (IF) Cell immunofluorescence was performed to co-stain PAPP-A and fibroblast and epithelial cell specific marker (respectively pan-Cytokeratin and Vimentin) by following the same procedure described above in “Tissue Analysis by IF” section. The cells were washed 3 times with PBS and fixed for 10 minutes with pre-chilled methanol at −20°C. The following diluted primary antibodies: rabbit Anti-Pappalysin-1 (Cat.PB9306; polyclonal, Boster Biological Technology, Pleasanton, USA); mouse-Anti pan-Cytokeratin (Cat.91420; monoclonal, Biolegend, San Diego, USA); mouse Anti-Vimentin (Cat.2707–1; monoclonal, Epitomics, Burlingame, USA), in 0.1% BSA in TBS, were incubated overnight at 4°C. The autofluorescence quenchers were omitted. Images were visualised and captured with 40X objective by using a fluorescence microscope BZ-X810 and the software BZ-X800 Viewer1.1.2.4 (Keyence, Germany). The scale on images was added by using BZ-X800 Analyser.1.1.2.4 software. Nasal Mucus Analysis by ELISA According to the manufacturer’s instruction, the following commercially available enzyme-linked immunosorbent assay (ELISA) kit were used to analyse the level of PAPP-A (No. E-UNEL-H0034; Elabscience, USA) and of Eosinophil Cationic Protein (ECP) (ab279415; Abcam, Netherlands), in CRSwNP mucus (n=67). The samples were diluted (1:2) in 1xPBS. The obtained values were normalised on the total protein concentration of the samples. The results were reported as nanograms per millilitre of protein (ng/mL of protein).17 Statistical Analysis All experimental data are expressed as mean ± standard deviation. Graphics and data were analysed using GraphPad Prism 10.2.0 software. The Chi-square test was used to analyse data on gender, prior sinus surgery, allergy, asthma and smoking. One-way ANOVA test was used for data of age. The correlation analysis was made by Pearson’s test. Eosinophilic infiltration nominal data, absent, low/focal and high, were respectively assigned to numerical data: “0”, “1”, “2”. Eventually, the data was tested by Kruskal–Wallis. A p-value <0.05 was used to detect significant differences between the groups. Results Patient Demographics The patient samples included in this study were used as shown in Figure 1. Table 1 shows demographic data of all included patients. There were no significant differences between CRSwNP (n=108), CRSsNP (n=12) and control (n=12) groups with respect to gender, environmental allergy, smoking and prior sinus surgery. However, significant differences were observed concerning age, asthma and previous sinus surgery in CRSwNP comparing to control and CRSsNP. Flow chart of CRSwNP, CRSsNP and control patients’ samples used for this study. Table 1Patient Demographics. Demographics Data of CRSwNP, CRSsNP and Control PatientsCharacteristics in %CRSwNP (n=108)CRSsNP (n=12)Control (n=12)p-ValueAge (years), mean ± SD50.1±14.940.1±15.332.6±12.8p<0.001GenderMale72/108 (66.6)7/12 (58.3)6/12 (50)p=0.46Female36/108 (33.3)5/12 (41.7)6/12 (50)p=0.46ComorbidityAsthma34/108 (31.5)1/12 (0.8)0/12 (0)p=0.02Environmental allergy61/108 (56.5)4/12 (33.4)5/12 (41.6)p=0.22AERD/NERD16/108 (14.8)0/120/12p=0.13Smoker28/108 (25.9)5/12 (41.7)2/12 (16.7)p=0.36Prior sinus surgery37/108 (34.2)2/12 (16.7)0/12 (0)p=0.02Abbreviations: AERD, aspirin-exacerbated respiratory disease; NERD, NSAID-exacerbated respiratory disease; CRSwNP, chronic rhinosinusitis with nasal polyps; CRSsNP, chronic rhinosinusitis without nasal polyps; SD, standard deviation. Patient Demographics. Demographics Data of CRSwNP, CRSsNP and Control Patients Abbreviations: AERD, aspirin-exacerbated respiratory disease; NERD, NSAID-exacerbated respiratory disease; CRSwNP, chronic rhinosinusitis with nasal polyps; CRSsNP, chronic rhinosinusitis without nasal polyps; SD, standard deviation. PAPP-A Distribution in CRSwNP Showed Three Distinct Patterns IHC staining was performed in order to localize PAPP-A in CRSwNP tissue (n=41), in middle turbinate (n=5) and in ethmoid tissue (n=7) from patients with CRSsNP and in control tissue (n=12). PAPP-A was highly intense in CRSwNP tissue, exhibiting three distinct distribution patterns significantly associated with eosinophil abundancy (p<0.001) (Figure 2A): 1) CRSwNP without eosinophil infiltration (CRSwNP-Epi) exhibits high intensity of PAPP-A only in goblet cells along with a weak expression in ciliated epithelium. Conversely, PAPP-A was not present in the basal epithelium layer (Figure 2Bi); 2) CRSwNP with significant high eosinophils (CRSwNP-E) revealed high PAPP-A staining only in mesenchymal cells thought to consist of eosinophils and fibroblasts (Figure 2Bii); 3) CRSwNP with focal eosinophil infiltration (CRSwNP-M) illustrated with the presence of PAPP-A in both the epithelial layer and the infiltration cells (Figure 2Biii). PAPP-A distribution in nasal tissues. (A) Correlation between eosinophil abundance and PAPP-A patterns in CRSwNP tissue. (B) Immunohistochemistry of PAPP-A in nasal tissues. i, ii, iii) CRSwNP tissue. (i) the panel shows a densely PAPP-A-positive epithelial layer with strong staining along the entire epithelial surface mainly in goblet cells, with an absence of staining in the mesenchyme. (ii) the panel shows a highly cellular mesenchymal compartment with abundant PAPP-A-positive cells widely distributed throughout the tissue. Numerous strongly positive cells are visible both in close proximity to the epithelium and deeply within the stroma. (iii) The epithelial lining strongly express PAPP-A and moderate isolated positive cells within the underlying mesenchyme. iv, v) CRSsNP. (iv) ethmoid tissue of CRSsNP; a few numbers of PAPP-A positive cells are visible both within the epithelial layer and throughout the subepithelial stroma. (v) middle turbinate of CRSsNP; only rare isolated PAPP-A positive cells are detectable, localized at the apical epithelial surface. The subepithelial mesenchyme is largely devoid of PAPP-A positive signal. (vi) control tissue; the epithelium shows prominent goblet cells expressing PAPP-A. The subepithelial region shows only rare positive cells. iv, v and vi) CRSwNP tissue. The arrows indicate PAPP-A staining in cells. Asterisks indicate statistically significant results (****<0.0001; **<0.001). Eosinophilic infiltration nominal data: absent, low/focal, high; were respectively assigned to numerical data: 0, 1, 2. Abbreviations: CRSwNP-E, chronic rhinosinusitis with nasal polyps with high eosinophils; CRSwNP-Epi, chronic rhinosinusitis with nasal polyps with absence of eosinophil infiltration; CRSwNP-Mix, chronic rhinosinusitis with nasal polyps with low eosinophil abundance; ns, not statistically significant. In the ethmoid tissue from CRSsNP patients, PAPP-A was less abundant with a medium intensity only in the apical layer of the epithelium and in the mesenchyme (Figure 2Biv). Besides, the middle turbinate of CRSsNP patients showed a minimal expression of PAPP-A in the ciliated cells, whereas it was non-existent in the basal layer of the epithelium and in the mesenchymal cells (Figure 2Bv). Finally, only weak staining in goblet and ciliated cells and in few mesenchymal cells was revealed in control tissue (Figure 2Bvi). Despite the absence of quantitative results on the level of PAPP-A expression in various cells, the IHC results demonstrated that PAPP-A is mainly synthesized by eosinophils rather than other cell types in different tissues based on the morphological features. PAPP-A Expression in CRSwNP Inflammatory Cells Based on previous studies, NP from CRS patients contained a high number of immune cells, including T-cells, B-cells, eosinophils and mast cells.8–10,18 In addition, the foregoing IHC staining results (Figure 2) showed an intense level of PAPP-A in NP. Therefore, a double IF was performed on CRSwNP tissue slides to highlight the presence of PAPP-A within different inflammatory cells. A co-staining of PAPP-A and cell specific marker for each inflammatory cell type was performed in CRSwNP-E tissues (n=6). The proteins tryptase, ECP, CD3e, CD20, CD163 and HNE were used as specific markers respectively in mast cells, eosinophils, T-cells, B-cells, macrophages and neutrophils. IF results showed a high expression of PAPP-A in eosinophils (Figure 3a), and a moderate expression in mast cells (Figure 3b). Interestingly, not all T cells express PAPP-A, as revealed in Figure 3c. Thus, some subtypes of T-cells were PAPP-A negative. However, PAPP-A was not expressed in B-cells, macrophages or neutrophiles (Figure 3d–f). Immunofluorescence for PAPP-A synthesis by inflammatory cells from CRSwNP. (a) Eosinophils; a moderate number of cells are visible in the field. A few cells display co-localization of ECP (red) and PAPP-A (green), appearing as an orange merged signal (indicated by arrow). (b) Mast-cells; a moderate number of cells are present. A few tryptase-positive mast cells (red) show co-localization with PAPP-A (green), as indicated by the arrows pointing to merged orange signal. (c) T-cells; a moderate number of cells are distributed across the field. Few CD3e-positive T-cells (red) show co-localisation with PAPP-A (green), as highlighted by the arrows. (d) B-cells; moderate cells are visible throughout the field. No evident co-localisation between CD20-positive B-cells (red) and PAPP-A (green) is observed. (e) Macrophages; a moderate number of cells are present with CD163-positive staining (red) distributed across the tissue. No co-localisation with PAPP-A (green) is detected. (f) Neutrophils; a moderate number of cells are visible. No evident co-localisation between HNE-positive staining (red) and PAPP-A (green) is observed. The arrows indicate the merged staining corresponding to PAPP-A and the specific biomarkers of inflammatory cells. Scale-bar: 50 µm. Localization of PAPP-A in Primary Fibroblasts and Epithelial Cell Primary epithelial and fibroblast cells from CRSwNP tissue (n=12) went through an immunofluorescence staining to emphasize a potential expression of PAPP-A. The results on (Figure 4) showed an intense expression of PAPP-A in both primary epithelial and fibroblast cells, mainly on the membrane, with a vesicular distribution shape in the cytoplasm. PAPP-A distribution in primary cells. Immunofluorescence of epithelial cells (figures a, b and c) and fibroblast cells (figures d, e and f) from CRSwNP. (a) pan-Cytokeratin staining (red); (b) and (e) PAPP-A staining (green); (d) Vimentin staining (red); (c) and (f) show the merged images. Nuclei were stained with DAPI (blue). Scale-bar: 50µm. Significant Association of PAPP-A and ECP in CRSwNP Mucus Based on the results of IHC and IF (Figures 2 and 3) in CRSwNP tissue, an ELISA assay was performed in order to analyse the presence of a correlation between PAPP-A level and the abundance of eosinophils non-invasively in CRSwNP mucus (n=67). The results revealed a strong significant positive correlation between PAPP-A and ECP expression (p<0.001) (Figure 5a). Furthermore, no significant association was observed between PAPP-A concentration in mucus and clinical comorbidities including asthma, allergy, AERD/NERD and IgE levels (Table 2). PAPP-A and eosinophil inflammation in CRSwNP patients. The scatter-plot (a) shows the correlation between PAPP-A and ECP in NM secretions of both cohorts of CRSwNP patients (n=67). The scatter-plot (b) shows the correlation between blood eosinophil and ECP in NM secretions of CRSwNP patients (n=67). Table 2Correlation Between Comorbidities and Blood Eosinophil in CRSwNP Patients (n=67) and Between ECP Level in Mucosa of CRSwNP Patients (n=67)CorrelationCRSwNP (n=67)CRSwNP (n=63)Blood EosinophilMucosal ECPPAPP-AAsthmap=0.85p=0.43p=0.89Environmental allergyp=0.93p=0.93p=0.28AERD/NERDp=0.79p=0.86p=0.77IgEp=0.33p=0.98p=0.48Abbreviations: ECP, eosinophil cationic protein; CRSwNP, chronic rhinosinusitis with nasal polyps. Correlation Between Comorbidities and Blood Eosinophil in CRSwNP Patients (n=67) and Between ECP Level in Mucosa of CRSwNP Patients (n=67) Abbreviations: ECP, eosinophil cationic protein; CRSwNP, chronic rhinosinusitis with nasal polyps. Circulatory and Local Eosinophil Correlation in CRSwNP Patients A correlation analysis was performed by using the data of blood eosinophil abundance in CRSwNP patients and the quantified ECP in CRSwNP mucus. The results obtained in (Figure 5b) show a high positive correlation between the circulatory eosinophils and local eosinophils in CRSwNP cases (n=67). In order to advance our investigation further, a statistical analysis was carried out based on patients’ data to uncover a possible link between eosinophil abundance (circulatory and local eosinophils) and comorbidities. According to Table 2, there is no correlation between eosinophil abundance and asthma, allergy, or AERD/NERD. Furthermore, IgE, the central mediator of inflammation in CRSwNP,19 also shows no correlation. Discussion Recently, studies from our group examining PAPP-A in CRSwNP patients identified a highly disrupted PAPP-A/IGFBP-4and-5/IGF-1-axis in tissue, RNA and exosomes.4 Also, PAPP-A concentration in nasal mucus was found to be an indicator for CRSwNP and asthma severeness.5,13 However, not much is yet known about PAPP-A expression sites and patterns in the sinuses on a tissular and cellular level, let alone during state of inflammation or tumor. Our data demonstrate the expression patterns of PAPP-A in inflamed tissues of different CRS phenotypes, in distinct inflammatory cells and in cell cultures of fibroblasts and epithelial cells of CRSwNP patients for the first time. Our IHC results support the previous finding that PAPP-A is overexpressed in CRSwNP tissues compared to CRSsNP and control tissue.5 PAPP-A showed different staining intensities in the epithelial layer and the mesenchyme, depending on the tissue type and the CRS phenotype. Inflamed tissue seems to generally induce PAPP-A synthesis. The CRSsNP middle turbinate showed only very weak PAPP-A staining inversely to the CRSsNP ethmoid, which could be due to less affection of the middle turbinate by the inflammation compared to the ethmoid. In CRSwNP, PAPP-A localisation was exhibiting three different patterns significantly correlated to the eosinophil infiltration profile. This outcome might highlight the potential inflammatory role of PAPP-A in different tissue layers, driving different outcomes. Furthermore, this could be a hint toward understanding the heterogeneity of the disease, thus, helping in the prognosis and the treatment strategy of CRSwNP. Besides, immunofluorescence of various inflammatory cells from CRSwNP tissue with a high eosinophils’ infiltration (CRSwNP-E) confirmed our assumption that PAPP-A synthesis is more prevalent among eosinophils than the other analysed cell types. Eosinophils play a critical role in the pathogenesis of inflammatory diseases such as CRSwNP by releasing pro-inflammatory factors that are directly involved in tissue damage.20 The synthesized PAPP-A by eosinophils could underline its role in maintaining the proliferative activity of eosinophils and neighbouring inflammatory cells, which could contribute to the development of the distinct CRS endotypes. In addition, since PAPP-A was proven to induce synthesis of inflammatory factors, MCP-1, TNF-α, and IL-6 mRNA and protein, in macrophages,11 it might support chronification in CRS. In accordance with these findings, PAPP-A correlation to ECP in CRSwNP-E mucus confirms its association to the eosinophil inflammation. ECP is an inflammation-related biomarker released by eosinophils, and it was proved to be increased in NP of CRSwNP-E patients.21,22 The absence of a significant correlation between PAPP-A levels and clinical comorbidities such as asthma, allergy and AERD/NERD further supports the notion that PAPP-A expression in this context reflects local inflammation within the sinonasal mucosa rather than systemic disease burden. Referring to previous findings, CRSwNP-E patients show a high NP recurrence risk, less improvement of quality of life, poor postoperative outcomes and severe sinus disease23,24 with incomplete understanding of the mechanism behind. Thus, PAPP-A may be involved in the resultant outcomes of CRSwNP and be part of the key regulators of eosinophils and surrounding cells in inflammation. Moreover, the presence of PAPP-A in CRSwNP-E mucosa possibly causes an inflammation in nearby healthy tissue, leading to consequent NP growth. Interestingly, our analysis demonstrated a positive significant correlation between circulatory and local eosinophil abundance in CRSwNP patients without any significant association with comorbidities. It was shown in a previous finding that CD69 (marker of eosinophil activation) was highly expressed in NP eosinophils compared to those in blood of CRSwNP patients, suggesting that the activation of eosinophils occurs initially at the local level.20 However, V. Dupuch et al demonstrated a pre-activation state of circulating eosinophils before their extravasation and migration to NP in CRSwNP patients.21 These evidences support our belief that inflammation in CRSwNP patients occurs not only at a sinus level, but also at the circulatory level without being affected by other comorbidities or inflammatory states. Further, that could reflect the state of eosinophil activation in NP by blood analysis for CRSwNP. Accordingly, non-invasive diagnosis can be performed in CRSwNP patients to verify the state of inflammation and describe the eosinophil abundancy in NP. Beyond inflammatory cells, PAPP-A was shown in previous studies to be highly expressed in human lung fibroblast, promoting the pulmonary fibrosis via IGF-1 activation.25 Fibroblasts have been shown to promote NP formation by producing a wide range of extracellular matrix components leading to a tissue remodelling.26,27 Fibroblasts are the main cells in connective tissue and they are found to be increased in CRSwNP,27 which could be explained by the involvement of the expressed PAPP-A in the activation of proliferation. To our knowledge, no investigation to date has described the distribution of PAPP-A in epithelial and fibroblast cells. Immunofluorescence of primary epithelial cells and fibroblasts in CRSwNP illustrated PAPP-A presence. Within the cells, the protein could be found in the membrane, cytosol, and partially in vesicles. More investigations are needed to explore the role of PAPP-A in different cell compartments. Some limitations of this study must be acknowledged. First, the classification of CRSwNP according to the infiltration profile of eosinophils was based on nominal data extracted from routine pathology reports, and the precise quantitative thresholds applied by the pathology department were not directly accessible. Secondly, the establishment of primary cell cultures from NP tissues has not always been successful and obtaining a pure primary cell population has remained technically challenging. Finally, further confirmation of these findings in larger study cohorts will be needed to validate the clinical relevance of identified PAPP-A expression patterns. Conclusion In conclusion, our work is the first to illustrate the three distinct patterns of PAPP-A expression in CRSwNP: high expression in inflammatory cells in eosinophil-dominant tissue (CRSwNP-E), expression in the epithelium and mesenchyme in cases with focal eosinophil infiltration (CRSwNP-M), and expression restricted to the epithelium in non-eosinophilic tissue (CRSwNP-Epi). These patterns were significantly correlated with the degree of eosinophil infiltration and may contribute to distinct disease outcomes, including higher recurrence risk and poorer postoperative prognosis in eosinophilic-CRSwNP. Furthermore, the expression of PAPP-A by different inflammatory cells suggests its implication in the chronicity of CRSwNP by promoting cell proliferation. These results provide new insights of PAPP-A pathway in CRSwNP pathogenesis. Acknowledgments Thanks to Renate Schäfer and Elisabeth Sterna from the Department of Otolaryngology, Head and Neck Surgery for methodological support. Funding Statement This study was funded by Deutsche Forschungsgemeinschaft (DFG 4627/4-1). The sponsor had no involvement in study design to submission of the paper for publication. Abbreviations ACS, acute coronary syndrome; AERD, aspirin-exacerbated respiratory disease; CRS, chronic rhinosinusitis; CRSsNP, Chronic rhinosinusitis without nasal polyp; CRSwNP, Chronic rhinosinusitis with nasal polyp; ECP, eosinophil cationic protein; FESS, functional endoscopic sinus surgery; ICAR-RS, international consensus statement on allergy and rhinology; IF, immunofluorescence; IHC, immunohistochemistry; IGFBP, insulin growth factor binding protein; IGF, insulin growth factor; NERD, NSAID-exacerbated respiratory disease; NM, nasal mucosa; NP, nasal polyp; PAPP-A, pappalysin; STC, stanniocalcin. Data Sharing Statement The data that support the findings of this study are available from the corresponding author, upon reasonable request. Ethical Approval The protocol and consent forms of this study are approved by the institutional review board of the University of Erlangen-Nürnberg (No.: 17-269_1-B) on 07.05.2019. All participants provided written informed consent prior to participating. This study complies with the Declaration of Helsinki. Author Contributions Afaf Ennahal: Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Visualization, Writing – original draft. Olaf Wendler: Conceptualization, Methodology, Resources, Software, Supervision, Validation, Visualization, Writing – review & editing. Vanessa Vivien Pesold: Software, Validation, Writing – review & editing. Sarina Katrin Mueller: Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Validation, Writing – review & editing. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. All authors have approved the final manuscript and provided their consent for publication. Disclosure Ms Afaf Ennahal reports that this paper was written within a PhD work that is financially supported by the Deutsche Forschungsgemeinschaft (DFG) during the conduct of the study. Prof. Dr. med. Sarina Mueller reports grants from the Deutsche Forschungsgemeinschaft during the conduct of the study, and grants from the German Research Foundation outside the submitted work. In addition, Prof. Dr. Sarina Mueller has a patent, 20724449.2, pending in Europe. The authors report no other conflicts of interest in this work. This article was performed in partial fulfillment of the requirements for obtaining the degree “Dr. rer. biol. hum.” at the FAU. The present work was performed in partial fulfilment of the requirements for obtaining the degree Dr.rer.biol.hum. Parts of this research were presented at the European Rhinologic Society (ERS) 2025 in Budapest and received the best basic research prize. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author, upon reasonable request.